

## **Supporting Information**

Structural basis of the atypical activation mechanism for KRAS V14I

**Asim K Bera<sup>1</sup>, Jia Lu<sup>1</sup>, Thomas E. Wales<sup>2</sup>, Sudershan Gondi<sup>1</sup>, Deepak Gurbani<sup>1</sup>, Andrew Nelson<sup>1</sup>, John R. Engen<sup>2</sup>,  
and Kenneth D. Westover<sup>1\*</sup>**

<sup>1</sup>Departments of Biochemistry and Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas,  
Dallas, Texas 75390, United States.

<sup>2</sup>Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115, United States.

**Running title:** Structural basis of KRAS V14I activation

\*Correspondence should be addressed to K.D.W. (Kenneth.Westover@UTSouthwestern.edu).


**Table S1.** HDX Data Summary and list of experimental parameters

<b>Data Set</b>	wild-type KRAS	V14I KRAS	A146T KRAS
<b>HDX reaction details<sup>a</sup></b>	Final D <sub>2</sub> O concentration=94.6%, pH <sub>read</sub> =7.6, 21 °C.		
<b>HDX time course</b>	0.083, 0.167, 1, 5, 10, 60, and 240 minutes		
<b>HDX controls</b>	6 undeuterated controls, three for each state		
<b>Back-exchange</b>	30-35%		
<b>Number of peptides<sup>b</sup></b>	64 followed	67 followed 56 coincident peptides followed	58 followed
<b>Sequence coverage</b>	92.3%	92.9% 77.5% coincident coverage	92.3%
<b>Average peptide length; Redundancy</b>	11.4;4.6		
<b>Replicates</b>	4 technical	2 technical	2 technical
<b>Repeatability</b>	+/- 0.30 relative Da		
<b>Significant differences</b>	> 0.8 Da		

<sup>a</sup> 18-fold dilution with labeling buffer [10mM Hepes, 150mM NaCl, 5mM MgCl<sub>2</sub> and 5  $\mu$ M GDP, 99.9% D<sub>2</sub>O (pD 8.0)]. 1-fold dilution with quench buffer [300 mM Sodium phosphate pH 2.47, H<sub>2</sub>O].


<sup>b</sup> Parameters to filter peptides for identification from the 6 undeuterated controls were: 2 consecutive products, 0.25 products per amino acid.

**Figure S1:** Side chain residues involved in interaction with GDP in (A) KRAS<sup>WT</sup> and (B) KRAS<sup>V14I</sup>. Figures are generated from crystal structures by using Maestro.





**Figure S2: Deuterium incorporation plots for all peptides followed in the HDX experiments**

### Mutation containing peptides




### Coincident peptides





**Figure S3:** Illustrating the relative differences in hydrogen-deuterium exchange mass spectrometry of KRAS<sup>V14I</sup> and KRAS<sup>A146T</sup>.



Illustrating the relative differences in hydrogen-deuterium exchange mass spectrometry of KRAS4B<sup>V14I</sup> and KRAS<sup>A146T</sup>. **(A)** Relative differences in deuterium incorporation shown in all peptides coincident between KRAS4B<sup>A146T</sup> vs KRAS<sup>WT</sup> (top panel) and KRAS4B<sup>V14I</sup> vs KRAS<sup>WT</sup> (bottom panel). The relative difference (y-axis) for each peptide is shown for each time point (time points are colored according to scale at the right). The peptides in the regions of mutation are not shown as a subtraction cannot be made against the wildtype (see uptake graphs in Figure S4 for comparison of deuterium levels in the peptides). **(B)** The differences in deuterium incorporation between the mutant and wild-type KRAS constructs at 5 time points are identified on the cartoon structures of KRAS<sup>A146T</sup> (top panel) and KRAS4B<sup>V14I</sup> (bottom panel). Relative differences are calculated as mutant minus wt KRAS and are colored according to the color scale at the bottom.